Chemomab Therapeutics

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary...

Fibrosis,monoclonal antibodies,primary sclerosisng cholangitis,scleroderma,and rare diseases

Chemomab therapeutics operates in the Pharmaceutical manufacturing industry.

Chemomab therapeutics's revenue is 11m - 100m

Chemomab therapeutics has 11 - 50 employees.